Richard S. Levy - Nov 1, 2024 Form 4 Insider Report for MADRIGAL PHARMACEUTICALS, INC. (MDGL)

Role
Director
Signature
/s/ Mardi Dier, as Attorney-in-Fact
Stock symbol
MDGL
Transactions as of
Nov 1, 2024
Transactions value $
-$1,467,903
Form type
4
Date filed
11/5/2024, 07:01 PM
Previous filing
Jul 1, 2024
Next filing
Nov 12, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MDGL Common Stock Options Exercise $36.8K +5K +45.41% $7.36 16K Nov 1, 2024 Direct
transaction MDGL Common Stock Sale -$840K -2.8K -17.49% $300.10 13.2K Nov 1, 2024 Direct F1, F2
transaction MDGL Common Stock Sale -$331K -1.1K -8.33% $301.22 12.1K Nov 1, 2024 Direct F1, F3
transaction MDGL Common Stock Sale -$242K -800 -6.61% $302.25 11.3K Nov 1, 2024 Direct F1, F4
transaction MDGL Common Stock Sale -$91.3K -300 -2.65% $304.29 11K Nov 1, 2024 Direct F1, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MDGL Stock Option (Right to Buy) Options Exercise $0 -5K -33.33% $0.00 10K Nov 1, 2024 Common Stock 5K $7.36 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 30, 2023.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $300.00 to $300.44, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $301.00 to $301.76, inclusive.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $302.11 to $302.30, inclusive.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $303.99 to $304.55, inclusive.
F6 The shares underlying this option are fully vested and exercisable.